Speaking Institutions
AACC, OSID, Hospital Albert Einstein, INTERFARMA, Brazilian Institute of Law Business Ethics and FADEPOF.
Speaking Companies
Laboratories Richmond, Bausch Health Companies, Novartis, ARTHREX, Odebrecht, upLexis, Uber, FIA Business School, Sanofi, Johnson & Johnson, Biogen, Allergan, Cristal, Laboratorios Bagó, CAC OAB/SP Pinheiros.
Who will
you meet?
Officers
General Counsels
Directors
Vice Presidents
- Ethics and Compliance
- Corporate Responsibility
- Quality Assurance
- International Contracts
- Corporate Compliance
- Legal Affairs
- Internal Audit
- Business Conduct
- Transparency Operations
- Private practice Lawyers
Sponsors
Program
1st day
What actions are public authorities taking towards promoting greater transparency in Latin America?
Monica da Luz Carvalho Soares
ANVISA, Brazil
Head of Knowledge, Innovation and Research (GGCIP)
Luis Rodrigo Piñeiro
ANMAT, Argentina
Direction of Institutional Relations and Advertising Regulation
Carolina Palhares Lima
Health Ministry, Brazil
Director of integrity
How to demonstrate and document compliance awareness and efforts
Martha Patricia Rivas Mandujano Bausch
Health Companies, Mexico
Regional Director Compliance Officer LatAm
Latam Fair Market Value Considerations
José Alfredo Sedano
Biogen, Mexico
Associate Legal Director & Compliance Officer Mexico & Colombia
2nd day
How to generate credibility in compliance programs
Felipe Dantas
CGU, Brazil
General Counsel
Legislative changes in relation to the criminal liability of companies and how it affects pharmaceutical companies in Chile
Giovanna Gardella
Laboratorios Bagó, Chile
Compliance Legal Adviser
Photo Gallery from Previous Events
Testimonials
-
"The main point was the people I met at the Congress, whose networking generated interviews and work placement alternatives for me."
Adriane Costa, Legal & Compliance Director At Compass Minerals
-
”It was an excellent opportunity to hear what the authorities industry, even sometimes what our competitors or other providers have to say about the topic.”
Alison Bascou, Sr. Regulatory Director at BD, France
-
"I think it's being an interesting event. Wherever there's discussion at top level, wherever there's respect. wherever there's an open forum, science can advance. It's very important to keep patient's well-being in mind and I think this forum allows that."
Jaime Uribe, CEO At PROBIOMED
-
“The strength of the biosimilar industry in our region is very encouraging. It seems to me this event is the propitious forum to share experiences and it is great.”
Tammy Boggiano Ayo, Process Development Director at CIM, Cuba
-
“It showed a broad picture, from a highly technical perspective up to a commercial viewpoint. It is not easy to get that in such a short period of time.”
Santiago Salguero, Executive Director at Pharmaceutical Association of Ecuador
-
“For companies like those I work for, i.e. suppliers to the pharmaceutical industry, this has been a great opportunity to see our clients’ perspective and above all to identify the major trends determining the future of biosimilars.”
Mauricio Roberto Hernández Morales, Key Account and Business Developer Manager at BD Mexico